课题基金 / 基金详情

ACTG A5229 (VS 10):TRIAL OF URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY

ACTG A5229 (VS 10):TRIAL OF URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY
ACTG A5229(VS 10):补充尿苷治疗 HIV 脂肪萎缩的试验
批准号:
7719530
负责人:
LISA A. KOSMISKI
金额:
$0.05万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2008-05-31

项目摘要

项目成果

LISA A. KOSMISKI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will try to see if taking a uridine supplement, NucleomaxX¿, is safe in HIV-infected persons and if it will reverse loss of fat in the face, arms, legs, or buttocks. The study will also try to see how well the study drug is tolerated. The study drug is a powdered nutritional food supplement that contains a substance called uridine. It comes in a sachet (packet) and needs to be mixed in with juice, milk, or water. The study drug is used in Europe as a food supplement but is not approved by the U.S. Food and Drug Administration (FDA) and is considered an experimental drug in the U.S.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Energy Expenditure in HIV Lipodystrophy
  • 批准号:
    7581280
  • 项目类别:
  • 资助金额:
    $30.12万
  • 财政年份:
    2009
  • 负责人:
    LISA A. KOSMISKI
  • 依托单位:
Energy Expenditure in HIV Lipodystrophy
  • 批准号:
    8037748
  • 项目类别:
  • 资助金额:
    $26.75万
  • 财政年份:
    2009
  • 负责人:
    LISA A. KOSMISKI
  • 依托单位:
Energy Expenditure in HIV Lipodystrophy
  • 批准号:
    8234081
  • 项目类别:
  • 资助金额:
    $26.75万
  • 财政年份:
    2009
  • 负责人:
    LISA A. KOSMISKI
  • 依托单位:
FRAM 2: FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION
  • 批准号:
    7719459
  • 项目类别:
  • 资助金额:
    $1.39万
  • 财政年份:
    2008
  • 负责人:
    LISA A. KOSMISKI
  • 依托单位:
海外基金